New drug aims to keep leukemia in remission after transplant

NCT ID NCT07040982

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing the drug asciminib as a maintenance treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who have already received a stem cell transplant or CAR T-cell therapy. The goal is to see if asciminib is safe and tolerable when given after these cellular therapies to help prevent the cancer from coming back. About 30 participants will be enrolled to evaluate side effects and the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: asciminib
What this could lead to: If it works, this could provide a new maintenance option to help keep leukemia from returning after transplant or CAR T-cell therapy.
What could go wrong: This is a very early phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to prevent relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) leukemia, acute lymphocytic, susceptibility to, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1

Contacts and locations

Locations

City of Hope Medical center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.